Sparsentan - Travere Therapeutics
Alternative Names: DARA; FILSPARI; PS-433540; RE-021Latest Information Update: 15 Sep 2025
At a glance
- Originator Bristol-Myers Squibb
- Developer CSL Vifor; Renalys Pharma; Retrophin; Travere Therapeutics
- Class Anti-inflammatories; Antihypertensives; Isoxazoles; Nerve growth factors; Small molecules; Spiro compounds; Sulfonamides; Urologics; Vascular disorder therapies
- Mechanism of Action Angiotensin type 2 receptor antagonists; Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed IgA nephropathy
- Preregistration Focal segmental glomerulosclerosis
- Phase II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Hereditary nephritis; Vasculitis
- Discontinued Hypertension
Most Recent Events
- 10 Sep 2025 The US FDA informed Travere Therapeutics that an advisory committee is no longer needed for Focal segmental glomerulosclerosis
- 10 Sep 2025 USFDA assigns PDUFA action date of 13/01/2026 for sNDA for Sparsentan for Focal segmental glomerulosclerosis
- 10 Sep 2025 Updated efficacy data from the phase-III DUPLEX trial in Focal segmental glomerulosclerosis released by Travere Therapeutics